Wildaliz Nieves

Wildaliz Nieves is a accomplished scientist with extensive experience in virology and immunology, currently serving as Senior Research Scientist I / Associate Director / Principal Scientist I at Gilead Sciences since July 2022. In this role, Wildaliz leads the development of clinical biomarker strategies for novel therapeutics targeting hepatitis D virus and COVID-19. Prior to Gilead Sciences, Wildaliz held positions at Nektar Therapeutics, where project management skills were utilized to direct biomarker program development and analysis, and at the University of California at San Francisco, focusing on clinical HIV immunology and mucosal immunology. Educational qualifications include a Ph.D. in Biomedical Sciences and a Master of Science in Public Health and Tropical Medicine from Tulane University.